ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2414

A Retrospective Comparative Analysis of Cardiovascular Risk Factors, Atherosclerotic Cardiovascular Disease and Statin Use as Secondary Prevention in a Cohort of Patients with Systemic Lupus Erythematosus versus Without Rheumatological Disease from a Single-Center Patient Registry

Alma Aveytia Camacho1, Rakesh Gullapelli2, Vineetha Philip3, Soudabeh Daliri1, Ruba Memon4, Helene DiGregorio2, Lily Romero Karam2, Kanika Monga3, Eleonora Avenatti2, Khurram Nasir2 and Myriam Guevara1, 1Houston Methodist, Houston, TX, 2Houston Methodist Hospital, Houston, TX, 3Houston Methodist Hospital, Sugar Land, TX, 4Houston Methodist, Missouri City, TX

Meeting: ACR Convergence 2024

Keywords: Atherosclerosis, Cardiovascular, prevention, risk factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased prevalence of cardiovascular risk factors (RFs), which predispose to higher risk of premature atherosclerotic cardiovascular disease (ASCVD). Similar to the general population, patients with SLE with established ASCVD should be initiated on statin therapy for secondary prevention. The goal of this study is to determine the prevalence of cardiovascular RFs and ASCVD in patients with SLE compared to patients without rheumatologic disease (RD) and to evaluate the use of statin as secondary prevention in both groups. To the best of our knowledge, this is the first and largest single-center based registry cohort describing RF, ASCVD and secondary prevention with statin use in a SLE population.

Methods: The Institutional electronic medical record (EMR)-linked registry (The Houston Methodist Learning Health System Outpatient Registry) was queried to identify patients with SLE based on ICD-10 codes, between June 2016 and December 2022. Patients seen in the system in the same timeframe with no ICD-10 codes identifying RDs were used as a comparator. Multivariate logistic regression models were used to determine the odds of cardiovascular RFs and ASCVD in SLE versus no-RD patients. In the subset of patients with established ASCVD, use of low-moderate and high intensity statin was compared among patients with SLE vs no-RD by age, gender and ethnicity. All analyses were performed using Stata version 17 and a p-value< 0.05 was considered statistically significant.

Results: A total of 1,140,294 patients were included in the study (8,452 patients with SLE and 1,131,842 with no known RD). Baseline demographics and clinical characteristics are summarized in Table 1. Age-adjusted prevalence of cardiovascular RFs demonstrated a significant higher prevalence of HTN (52.4% vs 36.7% p< 0.001), DM (17.1% vs 13.2%, p< 0.001), HLD (31.0% vs 24.6%, p< 0.001) and obesity (34.4% vs 29.8%, p< 0.001) in the SLE in comparison to the no-RD group.  Patients with SLE were significantly more likely to have CV RFs compared to no-RD patients (Figure 1a), of which HTN had the highest risk (OR 2.56 [2.44-2.69], p< 0.001). SLE patients also had higher age-adjusted ASCVD prevalence (12.9% vs 9.0%, p< 0.001) and its components of CAD (7.2% vs 5.6%, p< 0.001), PAD (2.6% vs 2.1%, p< 0.001) and stroke (5.9% vs 3.4%, p< 0.001). Similarly, SLE diagnosis carried increased risk of comorbid ASCVD compared to the no-RD cohort (Figure 1b). Finally, among patients with established ASCVD, there was a noticeable underuse of any intensity statin therapy in the SLE compared to the no-RD cohort (any statin 58.6% vs 71.7%, low-moderate statin 30.6% vs 34.5%; and high intensity statin 29.1% vs 38.2%, [p< 0.001 for all]). This statistically significant trend persisted across age and gender but not race (Figure 2).

Conclusion: This single-center large cohort showed higher prevalence and odds of ASCVD RFs and ASCVD in SLE compared to patients without RD. Moreover, in the subset of patients with SLE and established ASCVD, statins were largely underutilized. This is the first study to demonstrate suboptimal statin use as a secondary ASCVD prevention in the SLE patients despite higher cardiovascular burden in this population.

Supporting image 1

Table 1. Baseline characteristics

Supporting image 2

Figure 1. Odds ratio of cardiovascular RFs (a) and ASCVD (b) in patients with SLE vs no-RD

Supporting image 3

Figure 2. Utilization of statin among ASCVD patients across age, gender and race/ethnicity subgroups, stratified by SLE vs no-RD status


Disclosures: A. Aveytia Camacho: None; R. Gullapelli: None; V. Philip: None; S. Daliri: None; R. Memon: None; H. DiGregorio: None; L. Romero Karam: None; K. Monga: None; E. Avenatti: None; K. Nasir: None; M. Guevara: None.

To cite this abstract in AMA style:

Aveytia Camacho A, Gullapelli R, Philip V, Daliri S, Memon R, DiGregorio H, Romero Karam L, Monga K, Avenatti E, Nasir K, Guevara M. A Retrospective Comparative Analysis of Cardiovascular Risk Factors, Atherosclerotic Cardiovascular Disease and Statin Use as Secondary Prevention in a Cohort of Patients with Systemic Lupus Erythematosus versus Without Rheumatological Disease from a Single-Center Patient Registry [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/a-retrospective-comparative-analysis-of-cardiovascular-risk-factors-atherosclerotic-cardiovascular-disease-and-statin-use-as-secondary-prevention-in-a-cohort-of-patients-with-systemic-lupus-erythemat/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-retrospective-comparative-analysis-of-cardiovascular-risk-factors-atherosclerotic-cardiovascular-disease-and-statin-use-as-secondary-prevention-in-a-cohort-of-patients-with-systemic-lupus-erythemat/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology